LTA4H-IN-3, with the CAS number 2707473-09-2, is a small molecule inhibitor that targets the enzyme leukotriene A4 hydrolase (LTA4H). This enzyme plays a crucial role in the biosynthesis of leukotrienes, which are inflammatory mediators involved in various pathological conditions, including asthma and other inflammatory diseases. The compound is characterized by its ability to selectively inhibit LTA4H, thereby potentially modulating inflammatory responses. Its structure typically includes functional groups that enhance its binding affinity to the enzyme, contributing to its efficacy as an inhibitor. The pharmacological profile of LTA4H-IN-3 suggests that it may have therapeutic applications in treating conditions associated with excessive leukotriene production. As with many small molecule inhibitors, its solubility, stability, and bioavailability are important characteristics that influence its development as a therapeutic agent. Further studies are often required to fully understand its mechanism of action, potential side effects, and overall safety profile in clinical settings.

LTA4H-IN-3

2707473-09-2: LTA4H-IN-3, with the CAS number 2707473-09-2, is a small molecule inhibitor that targets the enzyme leukotriene A4 hydrolase (LTA4H). This enzyme plays a crucial role in the biosynthesis of leukotrienes, which are inflammatory mediators involved in various pathological conditions, including asthma and other inflammatory diseases. The compound is characterized by its ability to selectively inhibit LTA4H, thereby potentially modulating inflammatory responses. Its structure typically includes functional groups that enhance its binding affinity to the enzyme, contributing to its efficacy as an inhibitor. The pharmacological profile of LTA4H-IN-3 suggests that it may have therapeutic applications in treating conditions associated with excessive leukotriene production. As with many small molecule inhibitors, its solubility, stability, and bioavailability are important characteristics that influence its development as a therapeutic agent. Further studies are often required to fully understand its mechanism of action, potential side effects, and overall safety profile in clinical settings.

<p>LTA4H-IN-3 (compound 9) functions as an inhibitor of LTA4H, demonstrating an IC50 of 28 nM [1].</p>

CAS 2707473-09-2

LTA4H-IN-3

LTA4H-IN-3

Ref: TM-T86828